多中心老年HIV感染者队列中多拉韦林/多替拉韦双药组合的持久性
在意大利六中心老年HIV感染者队列中,157人曾启动多拉韦林/多替拉韦组合,中位随访27.85个月,8人(5.1%)因任何原因终止治疗,终止发生率为2.27/100人年,多因素Cox回归未发现终止的预测因素。作者认为该组合在临床复杂的老年HIV感染者中显示出良好的持久性。
要点
- 多拉韦林/多替拉韦组合虽未被指南提及,但真实世界数据开始出现。
- 157名老年HIV感染者中,中位随访27.85个月,8人(5.1%)终止治疗,发生率2.27/100人年。
- 多因素Cox回归未发现终止治疗的预测因素,可能因终止例数少且异质性大。
核心结论
- 在临床复杂的老年HIV感染者多中心队列中,多拉韦林/多替拉韦组合显示出良好的长期持久性,终止治疗概率很低,且似乎没有显著因素能预测终止,可能因终止例数有限且异质性大。
研究设计与样本
- 多中心意大利老年HIV感染者队列,纳入六个中心中所有曾启动多拉韦林/多替拉韦组合者,随访至2024年3月31日因任何原因终止治疗。
- 共纳入157人,采用描述性统计描述研究人群,用Kaplan-Meier曲线和Cox回归分析估计终止治疗的发生率及相关预测因素。
主要发现
- 157人中61.1%为男性,中位年龄59岁(IQR:55-64),75.2%有多病共存,38.9%存在多重用药,91.1%的HIV-RNA<50拷贝/mL。
- 19.4%启动多拉韦林/多替拉韦者无基因型耐药检测结果。
- 启动多拉韦林/多替拉韦的主要原因包括高心血管风险(51.6%)、简化治疗(52.9%)和药物相互作用(25.5%)。
- 中位随访27.85个月(IQR:22.92-31.79)期间,8人(5.1%)终止治疗(2例毒性、2例病毒学失败、2例换用长效药物、1例死亡、1例转诊),终止发生率为2.27/100人年随访。
- 多因素Cox回归分析未显示任何因素为终止治疗的预测因素。
临床怎么用
- 作者认为,在临床复杂的老年HIV感染者中,多拉韦林/多替拉韦组合显示出良好的持久性,终止治疗概率很低,且似乎没有显著预测因素。
局限性
- 终止治疗例数有限且异质性大,可能因此未发现显著预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Even though the doravirine/dolutegravir combination is not mentioned by guidelines, real-life data has begun to emerge on its use. We aimed to describe the durability of doravirine/dolutegravir in a multicentre Italian cohort of elderly people with HIV (EPWH). METHODS: We included all EPWH who ever started the doravirine/dolutegravir combination in six Italian centres and were followed up until treatment discontinuation (TD) for any reason (virological failure, death, treatment interruption for other reasons) on 31 March 2024. Descriptive statistics were used to describe the study population; Kaplan-Meier curves and Cox regression analyses were used to estimate incidence and associated predictors of time to TD. RESULTS: We included 157 people; 61.1% were male, the median age was 59 years (IQR: 55-64), 75.2% had multimorbidity, 38.9% were on polypharmacy, and 91.1% had HIV-RNA of <50 copies/mL. No genotype resistance test was available for 19.4% of people who started doravirine/dolutegravir. The main reasons for starting doravirine/dolutegravir were high cardiovascular risk (51.6%), simplification (52.9%) and drug-drug interactions (25.5%). During a median follow-up of 27.85 (IQR: 22.92-31.79) months, 8 (5.1%) participants experienced TD (2 toxicities, 2 virological failures, 2 switches to long-acting drugs, 1 death and 1 transferred). The incidence of TD was 2.27 per 100 person-years of follow-up. Multivariable Cox regression analyses did not show any factors as predictors of TD. CONCLUSIONS: In this multicentre cohort of EPWH with clinical complexity, the doravirine/dolutegravir combination showed good durability over time. TD probability was very low, and no significant factors seem to predict it, likely due to the limited number and heterogeneity of cases of TD.
引用
- Mazzitelli M, Cozzolino C, Gervasoni C, et al. Durability of doravirine/dolutegravir dual combination in a multicentre cohort of elderly people with HIV. J Antimicrob Chemother. 2025. PMID: 39928421. doi:10.1093/jac/dkaf039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。